Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age40-55
SponsorNorthwell Health
About this trial
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
Eligibility criteria
Qualifiers
PSA between 1.0 and 2.5 ng/dL
High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate cancer (father, brother) or specific genetic syndromes i.e. BRCA 1/2, HOX B13, Lynch syndrome, ATM, CHEK2
Patient is willing to participated in prostate cancer screening
Patient is capable of giving informed consent
Disqualifiers
Nodularity or firmness of prostate on exam
Patient has undergone a prior biopsy or prostate surgery
Patient is taking 5-alpha reductase inhibitors to manage benign prostatic hyperplasia, as this can significantly alter PSA levels.
Patient has a history of UTI or prostatitis in the preceding 6 months, as this can significantly alter PSA levels.
Trial design
Treatments tested in this trial
- Bi-parametric MRI
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov